A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma
Phase 1 – testing safety in a small group of people
Conditions:
Relapsed or Refractory Multiple Myeloma (R/R MM)
Sponsor: AbbVie Deutschland GmbH & Co. KG
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 30 participants
БГ